Advantages and Limits of Targeted Radionuclide Therapy with Somatostatin Antagonists

Elif Hindié, Clément Morgat, Paolo Zanotti-Fregonara, Magalie Haissaguerre, Laurence Bordenave, Antoine Tabarin
J Nucl Med. 2017-10-06; 59(3): 546-547
DOI: 10.2967/jnumed.117.202630


Lire sur PubMed

---

1. J Nucl Med. 2018 Mar;59(3):546-547. doi: 10.2967/jnumed.117.202630. Epub 2017 Oct
6.

Advantages and Limits of Targeted Radionuclide Therapy with Somatostatin
Antagonists.

Hindié E(1), Morgat C, Zanotti-Fregonara P, Haissaguerre M, Bordenave L, Tabarin
A.

Author information:
(1)Bordeaux University HospitalsHôpital Haut-Lévêque Avenue Magellan Pessac,
France E-mail: .

Comment in
J Nucl Med. 2018 Mar;59(3):547-548.

Comment on
J Nucl Med. 2017 Sep;58(9):1435-1441.

DOI: 10.2967/jnumed.117.202630
PMID: 28986513 [Indexed for MEDLINE]

Auteurs Bordeaux Neurocampus